4//SEC Filing
Bazemore Robert B 4
Accession 0000950170-24-107828
CIK 0001541157other
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 4:40 PM ET
Size
21.7 KB
Accession
0000950170-24-107828
Insider Transaction Report
Form 4
Bazemore Robert B
Director
Transactions
- Award
Stock Option (Right to Buy)
2024-09-17+5,000,000→ 5,000,000 totalExercise: $0.00Exp: 2034-09-17→ Ordinary Shares, par value $0.0001 per share (5,000,000 underlying)
Footnotes (3)
- [F1]The stock options have an exercise price of $0.001655 per ordinary share, par value $0.0001 per share ("Ordinary Share").
- [F2]Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. The stock option vests and becomes exercisable ratably in three equal installments with the first installment vesting on the date of the first Annual General Meeting ("AGM") following the date of the grant, and with the second and third installments vesting, respectively, on the dates of the second and third AGM's following the date of the grant, subject to the non-employee director's continued service with the Issuer.
- [F3]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
Documents
Issuer
Akari Therapeutics Plc
CIK 0001541157
Entity typeother
Related Parties
1- filerCIK 0001620152
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 4:40 PM ET
- Size
- 21.7 KB